Screening for connective tissue disease-associated antibodies by automated immunoassay

Willems, Philippe; Langhe, Ellen De; Claessens, Jolien; Westhovens, René; Hoeyveld, Erna Van; Poesen, Koen; Vanderschueren, Steven; Blockmans, Daniel Engelbert; Bossuyt, Xavier

doi:10.1515/cclm-2017-0905

Cited by 36 publications

(42 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in line with recent studies that showed that combining an immunoassay with ANA IIF adds value if the results of both tests are correctly judged in the context of the clinical manifestations of the patient (42,43). Furthermore, combining IIF with a solid-phase assay can assist in patient strati cation, especially in case of a low-positive ANA IIF titer (42,44,45). ICAP promotes to integrate the ANA IIF titer and pattern with advice for follow-up testing, taking into account the clinical presentation of the patient (10,46).…”

Section: Discussionsupporting

confidence: 89%

“…Clinicians and laboratory professionals considered that combined information on HEp-2 ANA and speci c tests for anti-ENA and anti-dsDNA antibodies is most informative. This is in line with recent studies that showed that combining an immunoassay with ANA IIF adds value if the results of both tests are correctly judged in the context of the clinical manifestations of the patient (42,43). Furthermore, combining IIF with a solid-phase assay can assist in patient strati cation, especially in case of a low-positive ANA IIF titer (42,44,45).…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey. 

Hoovels

Broeders

Chan

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundThe International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) has recently proposed nomenclature in order to harmonize ANA indirect immunofluorescence (IIF) pattern reporting. ICAP distinguishes competent-level from expert-level patterns. A survey was organized to evaluate reporting, familiarity, and considered clinical value of ANA IIF patterns. MethodsTwo surveys were distributed by European Autoimmunity Standardization Initiative (EASI) working groups, the International Consensus on ANA Patterns (ICAP) and UK NEQAS to laboratory professionals and clinicians. Results438 laboratory professionals and 248 clinicians from 67 countries responded. Except for dense fine speckled (DFS), the nuclear competent patterns were reported by >85% of the laboratories. Except for rods and rings, the cytoplasmic competent patterns were reported by >72% of laboratories. Cytoplasmic IIF staining was considered ANA positive by 55% of clinicians and 62% of laboratory professionals, with geographical and expertise-related differences. Quantification of fluorescence intensity was considered clinically relevant for nuclear patterns, but less so for cytoplasmic and mitotic patterns. Combining IIF with specific extractable nuclear antigens (ENA)/dsDNA antibody testing was considered most informative. Of the nuclear competent patterns, the centromere and homogeneous pattern obtained the highest scores for clinical relevance and the DFS pattern the lowest. Of the cytoplasmic patterns, the reticular/mitochondria-like pattern obtained the highest scores for clinical relevance and the polar/Golgi-like and rods and rings patterns the lowest. ConclusionThis survey confirms that the major nuclear and cytoplasmic ANA IIF patterns are considered clinically important. There is no unanimity on classifying DFS, rods and rings and polar/Golgi-like as a competent pattern and on reporting cytoplasmic patterns as ANA IIF positive.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 85%

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey. 

Hoovels

Broeders

Chan

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…We evaluated the performance of ANA for SLE diagnosis on 9851 unique consecutive patients tested for ANA (for description of the population, see Willems et al 7). All patients were tested for ANA by IIF (HEp-2000; ImmunoConcepts) and by solid-phase assay (EliA CTD screen; Thermo Fisher) 7. The clinical diagnosis was documented for 2475 patients, including (1) all patients who tested positive for IIF (cut-off 1:80) and/or CTD screen (cut-off ratio 0.7) and (2) a selection of 500 patients who tested double negative (including 150 patients with IIF titre 1:40) 7.…”

mentioning

confidence: 99%

Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities

Willems

Langhe²,

Westhovens

et al. 2018

Ann Rheum Dis

Self Cite

View full text Add to dashboard Cite

Acknowledgements We thank Laura Hendrickx, Marie-Christine Clukkers and Silke Willebrords for expert technical assistance. Contributors PW reviewed all the medical records of the patients included and performed the analysis. EDL, RW, SV and DB took care of the patients and helped with clinical classification of the patients. XB wrote a draft of the manuscript. All authors reviewed the draft and approved the submission of the manuscript.

show abstract

“…Indeed, the probability of identifying anti‐dsDNA and antibodies to extractable nuclear antigens increases with increasing ANA titres 2. Overall, the higher the antibody level, the higher the probability of an ANA-associated systemic rheumatic disease (AASRD) 3–5…”

mentioning

confidence: 99%

Titre-specific positive predictive value of antinuclear antibody patterns

et al. 2019

Self Cite

View full text Add to dashboard Cite

Screening for connective tissue disease-associated antibodies by automated immunoassay

Abstract: The positive predictive value for AASRD was higher for EliA than for IIF, but, depending on the disease, EliA might fail to detect antibodies that are detected by IIF. Combining immunoassay with IIF adds value.

Cited by 36 publications

References 19 publications

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey.

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey.

Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities

Titre-specific positive predictive value of antinuclear antibody patterns

Contact Info

Product

Resources

About

Screening for connective tissue disease-associated antibodies by automated immunoassay

Abstract: The positive predictive value for AASRD was higher for EliA than for IIF, but, depending on the disease, EliA might fail to detect antibodies that are detected by IIF. Combining immunoassay with IIF adds value.

Cited by 36 publications

References 19 publications

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey.&nbsp;

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey.&nbsp;

Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities

Titre-specific positive predictive value of antinuclear antibody patterns

Contact Info

Product

Resources

About

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey.

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey.